BEIJING, Aug. 9 (Xinhua) -- Chinese vaccine developer CanSinoBIO entered into a product supply framework agreement with AstraZenecaAB, under which CanSinoBIO will provide AstraZenecaAB with development and manufacturing services in support of its mRNA vaccine programme Tuesday, reported Cnr.cn.
Featuring simplification of craft, the mRNA technology platform established by CanSinoBIO can shorten the time of product development and rapidly achieve the industrialization of scientific research results. The company has completed the first phase of the mRNA vaccine production base project to support the R&D and commercialization of products based on the mRNA platform.
It is learned that based on CanSinoBIO's extensive experience and technology in developing, manufacturing and commercializing vaccine products, AstraZenecaAB's ongoing development of mRNA vaccines will focus on leveraging the company's mRNA production platform to advance its development of specific vaccines.
CanSinoBIO said that signing of the agreement is an important symbol of the company's ability to be recognized by international pharmaceutical companies, affirming the research and development strength and competitive advantage of CanSinoBIO in the mRNA technology field.
(Edited by Bao Nuomin with Xinhua Silk Road, baonuomin@xinhua.org)
A single purchase
